EVAX

NASDAQ 已收盘

Evaxion

2.25 USD
▲+0.22+10.84%
盘后 2.34 +3.83%
2026-11-20
市值
$20.75M
市盈率
—
EPS
-1.09
股息率
—
52 周区间
2.03 – 6.92
成交量
103.13K
Beta
0.56
目标价
12.25
52W 低 2.0352W 高 6.92
价格走势

公司简介

Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of advanced melanoma; EVX-03, DNA-based cancer vaccine for the treatment of solid tumors; and EVX-04, a therapeutic cancer vaccine candidate, which is in phase 1 trial for acute myeloid leukemia. Its programs also include vaccines that are in pre-clinical stage, which includes EVX-B1, a multi-component prophylactic vaccine targeting skin...